Compare ISTR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISTR | CRVS |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.9M | 546.7M |
| IPO Year | 2014 | 2016 |
| Metric | ISTR | CRVS |
|---|---|---|
| Price | $26.25 | $7.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $29.00 | $13.75 |
| AVG Volume (30 Days) | 49.9K | ★ 1.6M |
| Earning Date | 01-22-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 24.14 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $93,426,000.00 | N/A |
| Revenue This Year | $7.18 | N/A |
| Revenue Next Year | $70.45 | N/A |
| P/E Ratio | $11.79 | ★ N/A |
| Revenue Growth | ★ 12.93 | N/A |
| 52 Week Low | $15.39 | $2.54 |
| 52 Week High | $27.95 | $9.60 |
| Indicator | ISTR | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 39.32 |
| Support Level | $27.04 | $7.28 |
| Resistance Level | $27.64 | $7.86 |
| Average True Range (ATR) | 0.46 | 0.44 |
| MACD | -0.21 | -0.07 |
| Stochastic Oscillator | 5.03 | 10.00 |
Investar Holding Corp is a U.S.-based financial holding company. Through its subsidiaries, it offers a variety of commercial and retail lending products throughout its market areas, including business loans to small to medium-sized businesses, as well as loans to individuals. It has business operations spread across the United States and serves its customers through several service branches. The bank also offers cashiers' checks, direct deposit of payroll and Social Security checks, night depository, bank-by-mail, automated teller machines with deposit automation, and debit cards.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).